Innovative Medicines Canada

What Innovative Medicines Canada does

Innovative Medicines Canada (IMC) is the national trade association representing 40+ research-based pharmaceutical companies operating in Canada, founded in 1914 and headquartered in Ottawa, Ontario. The organization functions as the unified policy and advocacy voice of the Canadian innovative pharmaceutical industry, engaging federal and provincial governments, healthcare providers, patient groups, and private insurers on issues including drug access, pharmacare, patented medicine pricing, rare disease drug coverage, and private drug plan sustainability. IMC is governed by a Board of Directors composed of senior executives from member companies, currently chaired by Gaby Bourbara of AstraZeneca Canada, and led by President and CEO Dr. Bettina Hamelin.

IMC does not develop proprietary technology products. Its core deliverables are advocacy services (policy positions, government submissions, pre-budget consultations, press releases), compliance and ethics resources (the Code of Ethical Practices, competition law guidance, voluntary payment disclosure frameworks), information resources (analysis reports, the Canadian Public Reimbursement Timelines tool, Pharma 101 educational content), the Health Research Foundation, and stakeholder convening platforms including the Medicine Matters Canada advocacy platform launched in September 2025. The association operates standard web and email infrastructure plus a mobile app for ethics code distribution.

IMC's business model is a non-profit membership-funded model. Revenue is generated through membership dues from its 40+ pharmaceutical company members (including Pfizer, Merck, AstraZeneca, Novartis, Eli Lilly, Amgen, Sanofi, Roche, and others), supplemented by sponsorship grants (typically up to $10,000 per award) distributed to eligible external organizations through quarterly review. Pricing is not publicly disclosed. The organization employs 11-50 staff and serves Canadian patients, healthcare professionals, governments, and private insurers as downstream beneficiaries of its advocacy work.

Name

Innovative Medicines Canada

Legal name

Innovative Medicines Canada

Website

https://innovativemedicines.ca

Company type

Private

Founded year

1914

Operating status

Operating

Headcount range

51–100 employees

Short description

Innovative Medicines Canada is a national non-profit trade association founded in 1914 that represents 40+ research-based pharmaceutical companies, advocating for patient access, ethical industry practices, and supportive pharmaceutical policy with Canadian federal and provincial governments.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Trade Association

NAICS

Research and Development in the Social Sciences and Humanities (54172)

SIC

Services-Health Services (8000)

akta.pro primary industry

Health Technology Assessment (HTA) & Reimbursement Policy Bodies (HLAJACAF)

akta.pro secondary industries

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN), Healthcare & Life Sciences PR (MPAAADAD)

Keywords

• Pharmaceutical industry advocacy
• Drug policy advocacy
• Healthcare policy research
• Pharmaceutical trade association
• Drug reimbursement data

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership dues: Innovative Medicines Canada generates revenue through membership fees from its 40+ pharmaceutical company members. The association provides advocacy, policy representation, ethics compliance frameworks, and member services in exchange for membership dues.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Innovative Medicines Canada is a national trade association representing 40+ research-based pharmaceutical companies in Canada. The association provides unified advocacy with governments, ethics compliance frameworks (Code of Ethical Practices), policy positions, government submissions, market access support, and stakeholder collaboration services in exchange for membership dues. It also publishes industry data, reimbursement timelines, and educational resources.

Product overview

Innovative Medicines Canada (IMC) is a national trade association representing 40+ research-based pharmaceutical companies. Rather than offering a unified product platform, IMC provides a portfolio of advocacy services, research resources, and educational materials. Key offerings include: advocacy services with policy positions and government submissions; the Health Research Foundation supporting research initiatives; analysis, reports, and research publications including economic impact studies; pre-budget submissions to provincial governments; Pharma 101 educational resources; Canadian Public Reimbursement Timelines tracking tool; patient stories advocacy platform; and the Code of Ethical Practices compliance framework. In September 2025, IMC launched Medicine Matters Canada as its national advocacy platform. IMC is not a technology product company and does not offer software products, APIs, or AI-powered solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Health Research Foundation: A foundation of IMC focused on supporting health research initiatives in Canada
• Medicine Matters Canada
• Ethics Code App
• Canadian Consensus Framework for Ethical Collaboration

Quantifiable outcome

• 150,000 high-quality Canadian jobs supported by member companies
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

13 partnerships are on record, tiered flagship, core and secondary.

• Roche CanadaflagshipStrategic or Co-development Partner · 20 November 2025IMC and Roche Canada jointly established the Brigitte Nolet Scholarship for Indigenous Pathways into Life Sciences at York University, supporting Indigenous students pursuing careers in the life sciences sector.
• Coalition for Better Medicines (Coalition pour de meilleurs médicaments)coreStrategic or Co-development Partner · 10 June 2016IMC partnered with the Coalition for Better Medicines along with other healthcare organizations to adopt the Canadian Consensus Framework for Ethical Collaboration, establishing ethical standards for collaboration between patient organizations, healthcare professionals, and the pharmaceutical industry.
• Canadian Healthcare Association (Coalition canadienne des organismes de bienfaisance en santé)coreStrategic or Co-development Partner · 10 June 2016Partnership to adopt the Canadian Consensus Framework for Ethical Collaboration, representing leading Canadian healthcare organizations committed to ethical standards in the pharmaceutical sector.
• Canadian Medical Association (Association médicale canadienne)coreStrategic or Co-development Partner · 10 June 2016Co-developed the Canadian Consensus Framework for Ethical Collaboration establishing principles for ethical relationships between physicians, patient organizations, and the pharmaceutical industry.
• Canadian Nurses Association (Association des infirmières et infirmiers du Canada)coreStrategic or Co-development Partner · 10 June 2016Partnered to establish ethical collaboration standards for healthcare professionals and the pharmaceutical industry through the Canadian Consensus Framework for Ethical Collaboration.
• Canadian Pharmacists Association (Association des pharmaciens du Canada)coreStrategic or Co-development Partner · 10 June 2016Collaborated on the Canadian Consensus Framework for Ethical Collaboration establishing ethical guidelines for pharmacist-pharmaceutical industry relationships.
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)coreStrategic or Co-development PartnerIMC is a member of IFPMA, the global body representing the research-based pharmaceutical industry. This membership provides access to international standards including the Mexico City Principles for voluntary business ethics codes and supports global health initiatives.
• Ontario Institute for Cancer Research (OICR)secondaryStrategic or Co-development PartnerMember companies partner with OICR for cancer research collaboration, contributing to new treatments for Canadians.
• Neomed InstitutesecondaryStrategic or Co-development PartnerPartnership for pharmaceutical research and development collaboration supporting innovation commercialization in Canada.
• MaRS InnovationsecondaryStrategic or Co-development PartnerCollaboration with MaRS Innovation to accelerate discovery and development of new medicines through academic-industry partnerships.
• Centre for Drug Research and Development (CDRD)secondaryStrategic or Co-development PartnerPartnership supporting drug development research and commercialization of pharmaceutical innovations.
• BioTalent CanadasecondaryChannel Partner/ Reseller/ DistributorIMC maintains a platinum partnership with BioTalent Canada, providing member companies with reduced rates for job postings on Le PetriDish, Canada's bilingual biotech job board.
• Partners for Health InternationalsecondaryOthersIMC member companies have donated over 11 million treatments to 110+ countries through Partners for Health International, demonstrating commitment to global health outcomes beyond Canada.

Scale indicators6 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Pharmaceutical Research and Manufacturers of America (PhRMA): PhRMA is the US national trade association representing research-based pharmaceutical companies, making it the most direct structural peer to IMC. Both organizations advocate on drug pricing, reimbursement, IP, and access policies for member companies.
• European Federation of Pharmaceutical Industries and Associations (EFPIA): EFPIA represents the research-based pharmaceutical industry in Europe and operates a near-identical advocacy and policy model to IMC, including an EFPIA Code of Practice on relationships with healthcare professionals.
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): IFPMA is the global trade association of which IMC is a member. It provides the international ethics framework (Mexico City Principles) and global advocacy coordination that IMC participates in and extends to its members.
• Association of the British Pharmaceutical Industry (ABPI): ABPI is the UK's national pharmaceutical industry trade association with a comparable membership-based advocacy model, Code of Practice, and government relations focus on NHS pricing and market access — directly paralleling IMC's mandate in Canada.
• Medicines Australia: Medicines Australia represents research-based pharmaceutical companies in Australia and operates a Code of Conduct and advocacy framework structurally similar to IMC, including engagement on PBS reimbursement policy.
• Japan Pharmaceutical Manufacturers Association (JPMA): JPMA is Japan's national pharmaceutical industry trade association operating an equivalent membership-based advocacy model and Code of Practice. It is an IFPMA peer association alongside IMC, operating in a different geography with comparable functions.

Regional players

• BIOTECanada: BIOTECanada is the Canadian national industry association for biotechnology companies, making it a regional peer. While IMC represents research-based pharma, BIOTECanada covers biotech firms with overlapping Canadian policy and advocacy concerns.
• Canadian Generic Pharmaceutical Association (CGPA): CGPA represents generic pharmaceutical manufacturers in Canada and engages on the same PMPRB, pharmacare, and reimbursement policy files as IMC, making it an adjacent industry association peer on Canadian drug policy.
• MEDEC (Canada's Medical Technology Association): MEDEC represents medical device and technology companies in Canada. While focused on devices rather than medicines, MEDEC shares IMC's Canadian advocacy, Code of Ethics, and government relations infrastructure — they have jointly celebrated APEC ethics principles.

Others

• BioTalent Canada: BioTalent Canada is a national non-profit supporting biotech talent and HR needs, with which IMC maintains a platinum partnership. It is an ecosystem enabler rather than direct competitor, providing workforce infrastructure to IMC's member companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/innovativemeds
• Facebookfacebook.com/Innovativemeds
• LinkedInlinkedin.com/company/innovativemedicinescanada

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovative Medicines Canada